评估推测的Cav1.3抑制剂桂利嗪对醛固酮的抑制作用
在血管紧张素II刺激的HAC15细胞中,桂利嗪与硝苯地平均降低醛固酮浓度和CYP11B2表达;在15例原发性醛固酮增多症成人中开展前瞻性开放标签交叉试验,桂利嗪30mg每日三次未降低ARR,而硝苯地平缓释60mg每日一次降低ARR,两药均使PAC升高,尿THA无变化。
要点
- 桂利嗪和硝苯地平均降低HAC15细胞醛固酮浓度及CYP11B2表达。
- 临床剂量桂利嗪未降低原发性醛固酮增多症患者的ARR。
- 硝苯地平降低ARR,但两药均使PAC升高,尿THA无变化。
核心结论
- 桂利嗪在体外降低肾上腺皮质细胞醛固酮分泌,但在最大可溶浓度下效果不及非选择性钙通道阻滞剂硝苯地平。
- 临床剂量桂利嗪未降低原发性醛固酮增多症患者的血浆ARR,且与体外结果一致,劣于硝苯地平。
- 大剂量硝苯地平疗效有限可能归因于Cav1.3阻断不完全,或非L型钙通道在醛固酮分泌中起作用。
研究设计与样本
- 体外研究:分别用桂利嗪(1-30μM)或硝苯地平(1-100μM)处理血管紧张素II刺激的HAC15细胞,测定培养液醛固酮浓度,并行RNA提取和定量聚合酶链反应评估CYP11B2表达。
- 前瞻性、开放标签、交叉研究:纳入15例原发性醛固酮增多症成人,接受2周桂利嗪30mg每日三次或硝苯地平缓释60mg每日一次,间隔2周洗脱。
- 分层主要结局为ARR、尿THA和PAC的变化;血压变化为次要结局;对对数转换数据进行参数分析。
- 临床试验注册号:NCT05686993。
主要发现
- 体外:桂利嗪30μM使醛固酮浓度和CYP11B2倍数变化的平均改变±SEM分别为-0.47±0.05和-0.56±0.07;硝苯地平100μM分别为-0.59±0.05和-0.78±0.07。
- 临床交叉试验:硝苯地平降低ARR,桂利嗪未降低ARR(F=3.25;P=.047)。
- 两药均使PAC升高(F=4.77;P=.013),但尿THA无变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Primary aldosteronism (PA) is commonly caused by somatic mutations of CACNA1D encoding Cav1.3, one of the four L-type calcium channels. The over-the-counter drug, cinnarizine, fits the Cav1.3 crystal structure pore domain. OBJECTIVE: We hypothesized that Cav1.3 blockade by cinnarizine may achieve similar, or greater, reduction in aldosterone secretion than nonselective Cav1.2/1.3 blockade by nifedipine. METHODS: Separate wells of angiotensin II-stimulated HAC15 cells were treated with either cinnarizine (1-30 μM) or nifedipine (1-100 μM). Aldosterone concentrations were measured in culture medium; RNA extraction and quantitative polymerase chain reaction were performed to evaluate CYP11B2 expression. A prospective, open-label, crossover study was conducted of 15 adults with PA, treated with 2 weeks of cinnarizine 30 mg 3 times a day or nifedipine extended release 60 mg daily, separated by a 2-week washout. The hierarchical primary outcome was change in aldosterone-to-renin ratio (ARR), urinary tetrahydroaldosterone (THA), and plasma aldosterone concentration (PAC). Blood pressure change was a secondary outcome. Parametric analysis was undertaken on log-transformed data. (ClinicalTrials.gov: NCT05686993). RESULTS: Both drugs reduced aldosterone concentrations and CYP11B2 expression in vitro. Mean changes ± SEM in fold change of aldosterone concentrations and CYP11B2 were -0.47 ± 0.05 and -0.56 ± 0.07, respectively, with cinnarizine 30 μM and -0.59 ± 0.05 and -0.78 ± 0.07 with nifedipine 100 μM. In the clinical crossover trial, ARR was reduced by nifedipine but not cinnarizine (F = 3.25; P = .047); PAC rose with both drugs (F = 4.77; P = .013), but urinary THA was unchanged. CONCLUSION: A Cav1.3 ligand, cinnarizine, reduced aldosterone secretion from adrenocortical cells, but at maximum-soluble concentrations was less effective than the nonselective calcium blocker, nifedipine. At clinical doses, cinnarizine did not reduce plasma ARR in patients with PA, and, as in vitro, was inferior to nifedipine. The limited efficacy of high-dose nifedipine may be due to incomplete Cav1.3 blockade, or to a role for non-L-type calcium channels in aldosterone secretion.
引用
- Ng E, Lee YN, Taylor A, et al. Evaluation of Aldosterone Suppression by Cinnarizine, a Putative Cav1.3 Inhibitor. J Clin Endocrinol Metab. 2025. PMID: 40052842. doi:10.1210/clinem/dgaf081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。